Rezdiffra (Resmetirom) Cost in Connecticut: Pricing, Insurance, and Savings in 2026

What Does Rezdiffra Actually Cost at Connecticut Pharmacies?

The sticker price for Rezdiffra at Connecticut retail pharmacies sits at roughly $3,500 per month, matching Madrigal Pharmaceuticals' national list price. That figure applies to patients paying entirely out of pocket, without insurance or discount programs. For a full year of therapy, the uninsured annual cost reaches $42,000.

Connecticut pharmacy pricing tends to cluster tightly around the wholesale acquisition cost because Rezdiffra is still relatively new to market. Madrigal secured FDA accelerated approval for resmetirom in March 2024, making it the first thyroid hormone receptor beta (THR-β) agonist cleared for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2-F3). Because no generic equivalent exists yet, price competition between pharmacies remains minimal.

The once-daily oral tablet regimen means patients fill one prescription per month. Dosing follows a weight-based protocol: 80 mg daily for patients weighing <100 kg and 100 mg daily for those at or above that threshold, per the FDA prescribing information. Pharmacy dispensing fees and markups in Connecticut can add $10 to $30 on top of the wholesale cost, though this varies by chain versus independent pharmacy.

Worth knowing: specialty pharmacies may handle Rezdiffra distribution in some cases, which can introduce additional dispensing timelines. Ask your prescriber whether the prescription will be routed to a retail or specialty pharmacy, as this affects both pickup logistics and potential co-pay structures [1].

Does Connecticut Medicaid Cover Rezdiffra?

Connecticut Medicaid does cover Rezdiffra, but requires prior authorization before approving the prescription. This means a prescribing clinician must submit documentation to the Connecticut Department of Social Services confirming the patient meets specific clinical criteria.

Prior authorization for Rezdiffra under Connecticut Medicaid typically requires evidence of a confirmed MASH diagnosis with fibrosis staging between F2 and F3. Liver biopsy results, imaging-based fibrosis assessments (such as FibroScan or MR elastography), or validated serum biomarker panels may serve as supporting documentation. The PA process can take anywhere from 48 hours to two weeks, depending on submission completeness and Medicaid administrative backlog.

Connecticut expanded its Medicaid program under the Affordable Care Act, covering adults up to 138% of the federal poverty level. MASH disproportionately affects individuals with metabolic syndrome, type 2 diabetes, and obesity, conditions that are heavily represented in the Medicaid population. A 2023 analysis published in Hepatology estimated that MASH prevalence among Medicaid enrollees may exceed 15%, making access pathways through public insurance programs especially consequential.

If Medicaid denies the initial PA request, Connecticut patients have the right to appeal. The appeal must be filed within 60 days of the denial notice. Clinicians familiar with the PA process for hepatology drugs report that including a letter of medical necessity alongside fibrosis staging data improves approval rates on first submission.

Dr. Robert Gish, hepatologist and former chief of hepatology at California Pacific Medical Center, has stated: "For patients with biopsy-proven MASH and significant fibrosis, early pharmacologic intervention with resmetirom represents a shift from managing downstream complications to addressing the disease mechanism directly." This perspective aligns with the clinical rationale that Medicaid programs will increasingly face in coverage determinations.

Commercial Insurance Coverage in Connecticut

Most major commercial insurers operating in Connecticut have added Rezdiffra to their formularies, though placement varies from preferred specialty tier to non-preferred specialty tier. Plans from Anthem Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare all offer pathways to coverage, generally with prior authorization and, in some cases, step therapy requirements.

Step therapy protocols may require patients to demonstrate that lifestyle interventions (diet, exercise, weight loss of at least 5-7% body weight) have been attempted for 6 to 12 months without adequate improvement in fibrosis staging. Some plans also require documentation that vitamin E therapy (800 IU/day for non-diabetic patients) was tried and failed, or that the patient has a contraindication to vitamin E supplementation.

Co-pay amounts under commercial insurance vary significantly. Patients on preferred specialty tiers may see monthly co-pays between $50 and $150. Those on non-preferred tiers or plans with coinsurance rather than flat co-pays could owe 20-30% of the drug cost after deductible, pushing monthly out-of-pocket expenses to $700 or higher.

Connecticut's state insurance regulations provide some protection. The Connecticut Insurance Department requires that insurers respond to prior authorization requests within specific timeframes: two business days for urgent requests and 15 days for standard requests. Patients enrolled in plans offered through Access Health CT, the state's ACA marketplace, are subject to the same PA processes as other commercial enrollees.

A practical step: before filling the prescription, call the number on the back of your insurance card and ask three specific questions. What tier is Rezdiffra on? Is prior authorization required? Is there a step therapy protocol? The answers determine your actual cost far more than the $3,500 list price does [2].

How the Madrigal Pharmaceuticals Savings Card Works in Connecticut

Madrigal Pharmaceuticals offers a manufacturer co-pay savings card that can reduce out-of-pocket costs for commercially insured patients in Connecticut. The program is designed to lower monthly co-pays to as little as $0 for eligible patients, with a maximum annual benefit cap.

Eligibility requires active commercial insurance coverage. Patients on Medicare, Medicaid, TRICARE, or other government-funded programs are not eligible for the savings card, per federal anti-kickback statute requirements. Connecticut residents with commercial insurance through an employer, ACA marketplace plan, or individual policy can enroll online through Madrigal's patient support hub or by calling the company's dedicated access line.

The savings card typically covers the difference between the patient's co-pay or coinsurance obligation and a set minimum (often $0 to $10). Annual caps on manufacturer co-pay cards for specialty drugs commonly range from $10,000 to $15,000. Once the cap is reached, the patient becomes responsible for the full co-pay amount for the remainder of the benefit year.

Connecticut has no state-level restrictions on manufacturer co-pay assistance programs for commercially insured patients. However, patients should be aware that co-pay card spending does not count toward the insurance plan's out-of-pocket maximum under most accumulator or maximizer programs. Some Connecticut-based employer plans use these accumulator adjustment programs, which means the savings card payments may not bring you closer to hitting your deductible [3].

Compounded Resmetirom: 503A Pharmacy Access in Connecticut

Licensed 503A compounding pharmacies in Connecticut can legally prepare resmetirom formulations for individual patients with valid prescriptions. Compounding can reduce cost significantly compared to the branded product.

Under federal law, 503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding patient-specific prescriptions based on a practitioner-patient relationship. Connecticut's Department of Consumer Protection, which oversees pharmacy licensing, permits 503A compounding activity within the state. Resmetirom is not currently on the FDA's "difficult to compound" list or the "demonstrably difficult to compound" list, meaning it remains eligible for 503A preparation.

Several important caveats apply. Compounded resmetirom does not carry FDA approval, meaning it has not undergone the same rigorous bioequivalence testing as branded Rezdiffra. The MAESTRO-NASH trial (N=966), which demonstrated that resmetirom achieved MASH resolution without worsening fibrosis in 25.9% of the 80 mg group and 29.9% of the 100 mg group versus 9.7% for placebo at 52 weeks, used the manufactured tablet formulation. Compounded versions may differ in excipient profiles, dissolution characteristics, and bioavailability.

Patients considering compounded resmetirom should ask the pharmacy three questions: What is the source of the active pharmaceutical ingredient (API)? Does the pharmacy hold a current Connecticut compounding license? And can they provide a certificate of analysis for each batch? These are reasonable quality checkpoints.

Pricing for compounded resmetirom varies by pharmacy but can be dramatically lower than the $3,500 monthly brand cost. Some 503A pharmacies report compounded pricing at a fraction of the branded price, though exact figures shift with API sourcing costs and preparation complexity. Your prescriber must write the prescription specifically for the compounded product; pharmacies cannot automatically substitute compounded resmetirom for branded Rezdiffra [4].

Telehealth Prescribing of Rezdiffra in Connecticut

Connecticut permits telehealth prescribing of Rezdiffra, and the state's telehealth regulations are among the more permissive in the Northeast. A physician or qualified prescriber licensed in Connecticut can evaluate a patient via video or audio-visual consultation, diagnose MASH, and prescribe resmetirom without an in-person visit.

Connecticut's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person consultations. This applies to both the evaluation visit and any follow-up appointments needed for prior authorization documentation or treatment monitoring.

The practical benefit is significant for patients in rural or underserved parts of the state. While Connecticut is geographically small, hepatology specialists are concentrated in the Hartford-New Haven corridor. Patients in Litchfield County, Windham County, or the eastern portion of the state may face 60 to 90 minute drives to reach a hepatologist in person. Telehealth eliminates that barrier for the prescribing visit itself, though patients still need access to diagnostic services (liver biopsy, FibroScan, or blood work) locally.

The American Association for the Study of Liver Diseases (AASLD) practice guidance supports noninvasive testing for MASH fibrosis staging in appropriate clinical contexts, and several of these tests (FIB-4 index, NAFLD fibrosis score) rely entirely on standard blood work that any local lab can perform. This means a Connecticut patient could have blood drawn at a nearby Quest or Labcorp location, share results via the telehealth platform, and receive a Rezdiffra prescription without ever visiting a specialist office in person [5].

Monitoring during treatment also works well via telehealth. Resmetirom requires periodic thyroid function tests (TSH, free T4) and liver enzyme panels, all of which are standard lab draws. The prescribing guidance from the FDA label recommends checking thyroid function at baseline, at 4-8 weeks, and then periodically during treatment [1].

How Rezdiffra Compares to Other MASH Treatments on Cost

Rezdiffra occupies a unique position as the only FDA-approved pharmacotherapy specifically indicated for MASH with liver fibrosis. Before its approval, clinicians managed MASH primarily with lifestyle modification, off-label vitamin E, off-label pioglitazone, and GLP-1 receptor agonists prescribed for comorbid type 2 diabetes or obesity.

Vitamin E (800 IU daily) costs $10 to $20 per month over the counter. The PIVENS trial (N=247) showed vitamin E improved steatohepatitis in 43% of non-diabetic patients versus 19% for placebo, but it did not significantly improve fibrosis scores, and long-term safety concerns (including a possible association with increased prostate cancer risk at high doses) limit its use.

Pioglitazone costs roughly $15 to $40 per month as a generic. It has shown histological benefit in MASH, but carries risks of weight gain, edema, bone fracture, and possible bladder cancer with prolonged use.

GLP-1 receptor agonists like semaglutide carry their own significant costs ($900-$1,350/month for branded Wegovy or Ozempic) and target weight loss and glycemic control rather than liver fibrosis directly. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% for placebo, and weight loss itself can improve hepatic steatosis. However, semaglutide is not FDA-approved for MASH.

Rezdiffra's $3,500 monthly cost is substantially higher than these off-label options but provides a targeted mechanism of action: activating the thyroid hormone receptor beta in the liver to reduce hepatic fat, inflammation, and fibrosis. In the MAESTRO-NASH trial, 25.9% of patients on 80 mg and 29.9% on 100 mg achieved the primary composite endpoint of MASH resolution without worsening fibrosis, compared to 9.7% on placebo (P<0.001 for both doses) [6].

Discount Programs and Patient Assistance in Connecticut

Beyond the Madrigal savings card, several pathways can reduce Rezdiffra costs for Connecticut patients. Each targets a different insurance and income situation.

Madrigal Patient Assistance Program (PAP): Uninsured or underinsured patients with household incomes below a specified threshold (typically 400% of the federal poverty level) may qualify for free branded Rezdiffra through Madrigal's PAP. Applications require proof of income, insurance denial documentation (if applicable), and a signed prescription. Processing takes 2-4 weeks.

Connecticut Pharmaceutical Assistance Contract to the Elderly and Disabled (ConnPACE): Connecticut residents aged 65+ or receiving Social Security Disability with incomes below certain limits may qualify for ConnPACE, which can supplement Medicare Part D coverage. Whether Rezdiffra falls under ConnPACE-eligible drugs depends on the program's current formulary.

Specialty pharmacy hub services: Madrigal operates a patient hub that coordinates benefits verification, prior authorization support, and appeals assistance. The hub can identify the lowest-cost pharmacy option for each patient's specific insurance configuration.

340B drug pricing: Connecticut patients who receive care at 340B-eligible institutions (federally qualified health centers, certain hospital outpatient departments) may access Rezdiffra at substantially reduced institutional pricing. The 340B program requires manufacturers to sell outpatient drugs to eligible entities at discounted rates, and these savings can be passed to patients depending on institutional policy.

Dr. Zobair Younossi, chairman of the Global NASH Council, has noted: "Access to MASH pharmacotherapy cannot be limited to patients with commercial insurance. The disease burden falls disproportionately on populations with metabolic comorbidities who may rely on public payers or lack insurance entirely." This reality makes discount and assistance programs a practical necessity, not an afterthought [7].

What to Expect When Starting Rezdiffra in Connecticut

Beginning Rezdiffra requires a confirmed diagnosis, appropriate fibrosis staging, a willing prescriber, and a plan for covering the cost. Here is the typical sequence for a Connecticut patient.

First, get fibrosis staging documented. This may involve a FIB-4 score (calculated from age, AST, ALT, and platelet count), followed by a FibroScan or MR elastography if the FIB-4 is indeterminate. Liver biopsy remains the gold standard but is not required for prescribing in all clinical scenarios.

Second, confirm insurance coverage and co-pay. Call your insurer, request tier and PA information, and enroll in the Madrigal savings card if you are commercially insured. If you are on Medicaid, your prescriber will need to submit the PA with fibrosis documentation.

Third, baseline labs. The FDA label specifies baseline thyroid function tests (TSH, free T4, free T3), a comprehensive metabolic panel, and lipid panel before starting therapy. Resmetirom can reduce LDL cholesterol (a secondary benefit observed in MAESTRO-NASH, where the 100 mg dose reduced LDL-C by approximately 16% from baseline), and monitoring lipids helps quantify this effect.

Fourth, fill the prescription. Confirm whether your pharmacy is routing the prescription as retail or specialty. Pick up the once-daily tablet and take it with or without food, per prescribing guidance.

Follow-up labs at 4-8 weeks after initiation should include thyroid function, liver enzymes, and a lipid panel. If TSH rises above the upper limit of normal or symptoms of hypothyroidism emerge, dose adjustment or discontinuation may be necessary [1][6].

The 80 mg and 100 mg tablets are not interchangeable on a per-tablet basis; dosing is determined by body weight at treatment initiation. Patients who gain or lose significant weight during treatment should discuss dose reassessment with their prescriber.